Management of Left Apical Clot Anticoagulation

Choice of Anticoagulant

• The European Society of Cardiology recommends warfarin as the first-line therapy for left ventricular thrombus, with a target INR of 2.0-3.0 3, 4
• Direct oral anticoagulants (DOACs) are generally preferred over vitamin K antagonists (VKAs) for most indications requiring anticoagulation, except in patients with mechanical heart valves and mitral stenosis 1, 2

Duration of Anticoagulation

• Anticoagulation should be administered for up to 6 months for left ventricular thrombus, guided by repeated imaging to confirm thrombus resolution 3, 5
• For patients with persistent apical akinesia, even after thrombus resolution and LVEF improvement, extended anticoagulation may be warranted due to the risk of thrombus recurrence 3, 5

Monitoring and Follow-up

• Regular echocardiographic assessment is recommended to monitor thrombus resolution 3
• For patients on warfarin, the INR should be determined at least weekly during initiation of therapy and at least monthly when anticoagulation is stable 2
• Time in therapeutic range should be >70% for patients on warfarin 1

Special Considerations

• If a patient with left apical thrombus also has atrial fibrillation, the choice and duration of anticoagulation should follow the more stringent recommendations (typically lifelong therapy) 6
• Assessment and management of modifiable bleeding risk factors is recommended in all patients eligible for oral anticoagulation 7
• Bleeding risk scores should not be used to decide on starting or withdrawing anticoagulants 7

Common Pitfalls to Avoid

• Delaying anticoagulation in patients with confirmed left ventricular thrombus increases the risk of embolic events 3
• Premature discontinuation of anticoagulation before thrombus resolution or in patients with persistent wall motion abnormalities may lead to thrombus recurrence 3
• Inadequate INR monitoring for patients on warfarin therapy, which should be at least weekly during initiation and monthly when stable 2